Try our mobile app

Switch to company model in classical logic    *

General information

Country: UNITED STATES

Sector: Biotechnology

Coherus Biosciences, Inc. operates as a biopharmaceutical company. The Company develops biosimilar therapeutics to aid patients.
Website: coherus.com



Growth: Bad revenue growth rate -41.3%, there is slowdown compared to average historical growth rates 6.9%. The revenue growth dynamics is unstable

Profitability: LTM EBITDA margin is negative, -39.7%. On average the margin is decreasing steadily. In the last quarter the company did not beat the estimated EPS. The company was ahead of estimated EPS in 40% of quarters (showing a gain of -$0.14 per share on average)

Cash Flow Generation: Dividend yield for the last twelve months 0.0%. Free cash flow yield 138.2% (LTM)

Undervaluation: Fundamental value created in LTM (estimate)


Entry Point: Share price is 103.0% higher than minimum and 87.1% lower than maximum for the last 3 years

AI Insight: the companies with similar growth trajectories, EBITDA margin, industries and geography on average are valued -0.8x by EV / Sales multiple

Key Financials (Download financials)

Ticker: CHRS
Share price, USD:  (0.0%)1.36
year average price 1.1502  


year start price 1.5200 2024-12-23

min close price 0.7210 2025-06-25

max close price 1.8200 2025-10-09

current price 1.3600 2025-12-22
Common stocks: 115 418 069

Dividend Yield:  0.0%
EV / Sales: 1.1x
Margin (EBITDA LTM / Revenue): -39.7%
Fundamental value created in LTM:
Market Cap ($m): 157
Net Debt ($m): 139
EV (Enterprise Value): 296
Price to Book: 1.8x

Revenue and EBITDA

Quarterly values ($m)

Change (y/y)

Cash Flow

FCF ($m)

Net Debt / Cash and Equivalents ($m)

Share price and dividends (Download history)

Share price

Payment USD per share

Multiple and potential

EV / Sales

Potential dynamics

News


2025-11-06globenewswire.com

Arvind Sood joins Coherus Oncology as Chief Strategy and Corporate Affairs Officer

2025-10-01seekingalpha.com

Coherus Oncology, Inc. (CHRS) Presents at UBS Virtual Oncology Day Transcript

2025-08-09seekingalpha.com

Coherus Oncology, Inc. (CHRS) Q2 2025 Earnings Call Transcript

2025-08-07globenewswire.com

Coherus Oncology Reports Second Quarter 2025 Financial Results and Provides Business Update

2025-05-12seekingalpha.com

Coherus BioSciences, Inc. (CHRS) Q1 2025 Earnings Call Transcript

2025-05-01globenewswire.com

Coherus to Participate in Upcoming Investor Conferences

2025-04-17seekingalpha.com

Coherus BioSciences: Cleaning The Balance Sheet And Developing New Drugs

2025-03-10seekingalpha.com

Coherus BioSciences, Inc. (CHRS) Q4 2024 Earnings Call Transcript

2024-12-18globenewswire.com

Coherus to Present Final Phase 2 Casdozokitug Combination Data in Patients with Metastatic Hepatocellular Carcinoma at ASCO-GI 2025

2024-12-16seekingalpha.com

Coherus BioSciences: Shedding Pegfilgrastim To Fuel Ongoing Development
More information for subscribed users:
detailed calculation of
Fundamental value created in LTM

Financial reporting

Income Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-06 2024-08-08 2024-05-09 2024-03-15 2023-11-06 2023-08-02 2023-05-08 2023-03-06 2022-11-08
acceptedDate 2025-11-06 17:12:12 2025-08-07 16:55:06 2024-11-06 16:31:28 2024-08-08 16:39:04 2024-05-09 16:51:52 2024-03-15 17:13:21 2023-11-06 16:35:59 2023-08-02 16:11:32 2023-05-08 16:20:06 2023-03-06 16:16:08 2022-11-08 16:03:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
revenue 12M 10M 71M 65M 77M 92M 75M 59M 32M 45M 45M
costOfRevenue 4M 3M 21M 30M 36M 86M 33M 25M 17M 14M 35M
grossProfit 8M 7M 50M 35M 41M 6M 42M 34M 16M 31M 10M
grossProfitRatio 0.678 0.669 0.707 0.545 0.532 0.064 0.561 0.577 0.48 0.687 0.224
researchAndDevelopmentExpenses 27M 26M 22M 21M 27M 25M 26M 23M 34M 29M 46M
generalAndAdministrativeExpenses 0 0 0 0 0 0 0 0 0 0 0
sellingAndMarketingExpenses 0 0 0 0 0 0 0 0 0 0 0
sellingGeneralAndAdministrativeExpenses 23M 26M 35M 35M 50M 49M 48M 45M 49M 54M 45M
otherExpenses 2M 0 0 1M 3M -129 000 2M 2M 2M 2M 0
operatingExpenses 52M 52M 56M 56M 77M 74M 74M 68M 83M 83M 91M
costAndExpenses 56M 56M 77M 85M 113M 160M 107M 93M 100M 97M 126M
interestIncome 0 0 0 0 0 -30M 10M 10M 0 0 0
interestExpense 2M 2M 5M 5M 11M 11M -10M 10M 10M 9M 8M
depreciationAndAmortization 966 000 1M 2M 1M 2M 1M 899 000 880 000 2M 2M 2M
ebitda -41M -42M -4M -6M -34M -67M -32M -32M -66M -49M -78M
ebitdaratio -3.563 -4.054 -0.054 -0.297 -0.444 -0.735 -0.429 -0.546 -2.035 -1.091 -1.72
operatingIncome -44M -45M -6M -21M -36M -68M -32M -35M -68M -51M -80M
operatingIncomeRatio -3.831 -4.436 -0.09 -0.316 -0.464 -0.747 -0.429 -0.588 -2.089 -1.135 -1.771
totalOtherIncomeExpensesNet -184 000 624 000 -4M 8M 139M -11M -8M 2M -8M -7M -6M
incomeBeforeTax -45M -45M -11M -13M 103M -80M -40M -43M -76M -59M -87M
incomeBeforeTaxRatio -3.847 -4.375 -0.152 -0.199 1.335 -0.87 -0.537 -0.73 -2.335 -1.298 -1.908
incomeTaxExpense 0 0 0 0 1M -11M -380 000 12M -949 000 7M 6M
netIncome -36M 298M -11M -13M 103M -80M -40M -43M -75M -66M -93M
netIncomeRatio -3.071 29.039 -0.152 -0.199 1.335 -0.87 -0.532 -0.73 -2.305 -1.461 -2.044
eps -0.31 -0.36 -0.093 -0.11 0.91 -0.71 -0.41 -0.49 -0.94 -0.85 -1.19
epsdiluted -0.31 -0.36 -0.093 -0.11 0.82 -0.71 -0.41 -0.49 -0.94 -0.85 -1.19
weightedAverageShsOut 116M 116M 115M 115M 113M 111M 98M 87M 79M 78M 78M
weightedAverageShsOutDil 116M 116M 115M 115M 126M 111M 98M 87M 79M 78M 78M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Balance Sheet Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-06 2024-08-08 2024-05-09 2024-03-15 2023-11-06 2023-08-02 2023-05-08 2023-03-06 2022-11-08
acceptedDate 2025-11-06 17:12:12 2025-08-07 16:55:06 2024-11-06 16:31:28 2024-08-08 16:39:04 2024-05-09 16:51:52 2024-03-15 17:13:21 2023-11-06 16:35:59 2023-08-02 16:11:32 2023-05-08 16:20:06 2023-03-06 16:16:08 2022-11-08 16:03:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
cashAndCashEquivalents 103M 217M 98M 159M 260M 103M 80M 73M 16M 64M 287M
shortTermInvestments 88M 21M 0 0 0 15M 51M 72M 112M 128M 0
cashAndShortTermInvestments 192M 238M 98M 159M 260M 118M 131M 145M 128M 192M 287M
netReceivables 250M 120M 199M 314M 284M 261M 217M 141M 101M 110M 91M
inventory 2M 5M 48M 62M 62M 63M 67M 64M 114M 115M 28M
otherCurrentAssets 17M 18M 25M 23M 22M 35M 16M 18M 21M 23M 43M
totalCurrentAssets 461M 380M 369M 558M 627M 476M 444M 385M 344M 417M 448M
propertyPlantEquipmentNet 2M 2M 3M 3M 4M 11M 6M 7M 8M 9M 10M
goodwill 0 0 0 0 0 943 000 943 000 0 0 0 0
intangibleAssets 49M 52M 54M 55M 57M 71M 46M 6M 0 0 0
goodwillAndIntangibleAssets 49M 52M 54M 55M 57M 72M 47M 6M 6M 6M 6M
longTermInvestments 0 0 0 452 000 452 000 452 000 0 0 0 0 0
taxAssets 0 0 0 -1 0 71M 0 0 0 0 0
otherNonCurrentAssets 4M 5M 79M 58M 74M 87 000 87M 71M 45M 49M 87M
totalNonCurrentAssets 56M 59M 136M 117M 136M 154M 139M 84M 58M 64M 103M
otherAssets 0 0 0 1 1 0 0 0 0 0 0
totalAssets 517M 439M 505M 675M 764M 630M 584M 470M 402M 481M 551M
accountPayables 25M 38M 22M 77M 38M 35M 37M 29M 23M 12M 10M
shortTermDebt 2M 2M 2M 1M 177M 2M 4M 4M 4M 4M 4M
taxPayables 0 0 0 0 0 0 0 0 0 0 0
deferredRevenue 0 0 0 0 137M 0 -4M -4M 0 0 0
otherCurrentLiabilities 347M 226M 272M 385M 187M 294M 203M 140M 28M 39M 157M
totalCurrentLiabilities 374M 265M 296M 463M 538M 332M 240M 169M 56M 54M 171M
longTermDebt 39M 39M 232M 294M 300M 473M 474M 475M 472M 471M 477M
deferredRevenueNonCurrent 0 0 0 4M -353M 5M 0 0 0 0 0
deferredTaxLiabilitiesNonCurrent 1M 1M 1M 1M 1M 1M 0 0 0 0 0
otherNonCurrentLiabilities 15M 14M 65M 632 000 359M 11M 4M 102 000 72M 93M 463M
totalNonCurrentLiabilities 55M 55M 297M 296M 307M 491M 478M 475M 543M 564M 477M
otherLiabilities 0 0 0 1 0 0 0 0 0 0 0
capitalLeaseObligations 4M 4M 2M 6M 5M 5M 6M 7M 8M 9M 10M
totalLiabilities 429M 320M 593M 759M 845M 823M 717M 644M 599M 618M 648M
preferredStock 0 0 0 0 0 0 0 0 0 0 0
commonStock 12 000 12 000 12 000 12 000 11 000 11 000 11 000 9000 8000 8000 7000
retainedEarnings -1 345M -1 310M -1 500M -1 490M -1 477M -1 580M -1 500M -1 460M -1 417M -1 342M -1 283M
accumulatedOtherComprehensiveIncomeLoss -203 000 -275 000 -275 000 -272 000 -272 000 -248 000 -265 000 -297 000 -278 000 -249 000 -270 000
othertotalStockholdersEquity 1 433M 1 430M 1 413M 1 406M 1 395M 1 386M 1 367M 1 286M 1 221M 1 204M 1 186M
totalStockholdersEquity 88M 120M -88M -84M -82M -193M -134M -175M -197M -137M -97M
totalEquity 88M 120M -88M -84M -82M -193M -134M -175M -197M -137M -97M
totalLiabilitiesAndStockholdersEquity 517M 439M 505M 675M 764M 630M 584M 470M 402M 481M 551M
minorityInterest 0 0 0 0 0 0 0 0 0 0 0
totalLiabilitiesAndTotalEquity 517M 439M 505M 675M 764M 630M 584M 470M 402M 481M 551M
totalInvestments 88M 21M 0 452 000 452 000 15M 51M 72M 112M 128M 0
totalDebt 41M 41M 232M 298M 481M 481M 479M 479M 472M 471M 481M
netDebt -63M -176M 134M 139M 221M 378M 398M 406M 455M 408M 194M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Cash Flow Statement

Property 2025 q3 2025 q2 2024 q3 2024 q2 2024 q1 2023 q4 2023 q3 2023 q2 2023 q1 2022 q4 2022 q3
date 2025-09-30 2025-06-30 2024-09-30 2024-06-30 2024-03-31 2023-12-31 2023-09-30 2023-06-30 2023-03-31 2022-12-31 2022-09-30
symbol CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS CHRS
reportedCurrency USD USD USD USD USD USD USD USD USD USD USD
cik 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M 2M
fillingDate 2025-11-06 2025-08-07 2024-11-06 2024-08-08 2024-05-09 2024-03-15 2023-11-06 2023-08-02 2023-05-08 2023-03-06 2022-11-08
acceptedDate 2025-11-06 17:12:12 2025-08-07 16:55:06 2024-11-06 16:31:28 2024-08-08 16:39:04 2024-05-09 16:51:52 2024-03-15 17:13:21 2023-11-06 16:35:59 2023-08-02 16:11:32 2023-05-08 16:20:06 2023-03-06 16:16:08 2022-11-08 16:03:00
calendarYear 2025 2025 2024 2024 2024 2023 2023 2023 2023 2022 2022
period Q3 Q2 Q3 Q2 Q1 Q4 Q3 Q2 Q1 Q4 Q3
netIncome -36M 298M -11M -13M 103M -80M -40M -43M -76M -59M -87M
depreciationAndAmortization 966 000 1M 2M 1M 2M 1M 899 000 880 000 949 000 1M 995 000
deferredIncomeTax 0 0 0 0 0 -70M 874 000 -1M 0 0 0
stockBasedCompensation 3M 5M 7M 7M 7M 11M 10M 10M 12M 12M 12M
changeInWorkingCapital -9M -24M -63M 74M -11M 6M -28M -6M -9M -55M 9M
accountsReceivables -4M 55M 8M 77M 9M -44M -75M -40M 9M -19M 25M
inventory 2M 4M 21M -7M -11M -12M -19M -13M -3M -10M -23M
accountsPayables -15M -12M -50M 39M 616 000 -785 000 7M 6M 12M 2M -8M
otherWorkingCapital 8M -70M -41M -35M -9M 63M 60M 41M -27M -28M 15M
otherNonCashItems -6M -327M 3M -109M -134M 118M 1M 468 000 3M 754 000 28M
netCashProvidedByOperatingActivities -46M -47M -62M 60M -47M -13M -54M -39M -69M -100M -37M
investmentsInPropertyPlantAndEquipment 0 0 0 0 0 -34 000 0 -100 000 -152 000 -87 000 -457 000
acquisitionsNet 0 0 0 228M 0 76 000 151 000 440 000 0 0 0
purchasesOfInvestments -69M -21M 0 0 0 178 000 0 -20M 0 -127M 0
salesMaturitiesOfInvestments 2M 0 0 228M 15M 36M 43M 61M 18M 0 0
otherInvestingActivites -27 000 483M 444 000 -200M 188M -1M 7M 0 178 000 -2M 0
netCashUsedForInvestingActivites -67M 463M 444 000 28M 203M 35M 51M 41M 18M -130M -457 000
debtRepayment 0 -233M -141 000 -187M 0 0 0 0 0 -191M 0
commonStockIssued 0 188 000 -976 000 633 000 2M 891 000 11M 54M 7M 6M 0
commonStockRepurchased 0 0 2M 0 -745 000 -326 000 -175 000 -305 000 0 0 0
dividendsPaid 0 0 0 0 0 0 0 0 0 0 0
otherFinancingActivites 2000 -49M -26 000 -1M -911 000 -525 000 -157 000 1M -3M 191M 49M
netCashUsedProvidedByFinancingActivities 2000 -282M -167 000 -188M 887 000 366 000 11M 54M 4M 7M 49M
effectOfForexChangesOnCash 0 0 0 0 0 -452 000 3M 0 0 0 0
netChangeInCash -114M 134M -61M -101M 157M 22M 7M 57M -47M -223M 11M
cashAtEndOfPeriod 104M 217M 98M 159M 260M 103M 81M 73M 17M 64M 287M
cashAtBeginningOfPeriod 217M 83M 159M 260M 103M 81M 73M 17M 64M 287M 276M
operatingCashFlow -46M -47M -62M 60M -47M -13M -54M -39M -69M -100M -37M
capitalExpenditure 0 0 0 0 0 -34 000 0 -100 000 -152 000 -87 000 -457 000
freeCashFlow -46M -47M -62M 60M -47M -13M -54M -39M -69M -100M -38M
link Link Link Link Link Link Link Link Link Link Link Link
finalLink Link Link Link Link Link Link Link Link Link Link Link

Earning call transcript

2025 q3
2025-11-07 ET (fiscal 2025 q3)
2025 q2
2025-08-09 ET (fiscal 2025 q2)
2025 q1
2025-05-12 ET (fiscal 2025 q1)
2024 q4
2025-03-10 ET (fiscal 2024 q4)
2024 q3
2024-11-06 ET (fiscal 2024 q3)
2024 q1
2024-05-10 ET (fiscal 2024 q1)
2023 q4
2024-03-13 ET (fiscal 2023 q4)
2023 q3
2023-11-07 ET (fiscal 2023 q3)
2023 q2
2023-08-02 ET (fiscal 2023 q2)
2023 q1
2023-05-08 ET (fiscal 2023 q1)
2022 q4
2023-03-06 ET (fiscal 2022 q4)
2022 q3
2022-11-08 ET (fiscal 2022 q3)
2022 q2
2022-08-07 ET (fiscal 2022 q2)
2022 q1
2022-05-05 ET (fiscal 2022 q1)

SEC forms

Show financial reports only

SEC form 8
2025-11-13 17:13 ET
Coherus Biosciences published news for 2025 q3
SEC form 8
2025-11-13 17:13 ET
Coherus Biosciences published news for 2025 q3
SEC form 8
2025-11-13 17:13 ET
Coherus Biosciences published news for 2025 q3
SEC form 10
2025-11-06 17:12 ET
Coherus Biosciences reported for 2025 q3
SEC form 8
2025-11-06 16:28 ET
Coherus Biosciences published news for 2025 q3
SEC form 8
2025-11-06 16:28 ET
Coherus Biosciences reported for 2025 q3
SEC form 10
2025-08-07 20:55 ET
Coherus Biosciences reported for 2025 q2
SEC form 8
2025-08-07 20:53 ET
Coherus Biosciences published news for 2025 q2
SEC form 8
2025-08-07 20:53 ET
Coherus Biosciences reported for 2025 q2
SEC form 10
2025-05-12 20:59 ET
Coherus Biosciences reported for 2025 q1
SEC form 8
2025-05-12 20:39 ET
Coherus Biosciences published news for 2025 q1
SEC form 8
2025-05-12 20:39 ET
Coherus Biosciences reported for 2025 q1
SEC form 10
2025-05-12 00:00 ET
Coherus Biosciences reported for 2025 q1
SEC form 8
2025-04-14 12:00 ET
Coherus Biosciences published news for 2025 q1
SEC form 8
2025-04-14 12:00 ET
Coherus Biosciences published news for 2025 q1
SEC form 8
2025-04-14 12:00 ET
Coherus Biosciences published news for 2025 q1
SEC form 8
2025-04-01 20:10 ET
Coherus Biosciences published news for 2025 q1
SEC form 8
2025-04-01 20:10 ET
Coherus Biosciences published news for 2025 q1
SEC form 8
2025-04-01 20:10 ET
Coherus Biosciences published news for 2025 q1
SEC form 10
2025-03-17 20:28 ET
Coherus Biosciences published news for 2024 q4
SEC form 10
2025-03-17 00:00 ET
Coherus Biosciences published news for 2024 q4
SEC form 8
2025-03-10 16:31 ET
Coherus Biosciences published news for 2024 q4
SEC form 8
2025-03-10 16:31 ET
Coherus Biosciences reported for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Coherus Biosciences published news for 2024 q4
SEC form 8
2025-01-13 00:00 ET
Coherus Biosciences published news for 2024 q4
SEC form 10
2024-11-06 16:31 ET
Coherus Biosciences reported for 2024 q3
SEC form 8
2024-11-06 16:23 ET
Coherus Biosciences published news for 2024 q3
SEC form 8
2024-11-06 16:23 ET
Coherus Biosciences published news for 2024 q3
SEC form 10
2024-08-08 16:39 ET
Coherus Biosciences reported for 2024 q2
SEC form 8
2024-08-08 16:23 ET
Coherus Biosciences published news for 2024 q2
SEC form 8
2024-08-08 16:23 ET
Coherus Biosciences published news for 2024 q2
SEC form 10
2024-08-08 00:00 ET
Coherus Biosciences published news for 2024 q2
SEC form 10
2024-05-09 00:00 ET
Coherus Biosciences reported for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Coherus Biosciences published news for 2024 q1
SEC form 8
2024-05-09 00:00 ET
Coherus Biosciences published news for 2024 q1
SEC form 10
2024-03-15 17:13 ET
Coherus Biosciences published news for 2023 q4
SEC form 10
2024-03-15 00:00 ET
Coherus Biosciences published news for 2023 q4
SEC form 8
2024-03-13 16:16 ET
Coherus Biosciences published news for 2023 q4
SEC form 8
2024-03-13 16:16 ET
Coherus Biosciences reported for 2023 q4
SEC form 8
2024-01-10 00:00 ET
Coherus Biosciences published news for 2023 q4
SEC form 8
2024-01-10 00:00 ET
Coherus Biosciences published news for 2023 q4
SEC form 10
2023-11-06 16:35 ET
Coherus Biosciences reported for 2023 q3
SEC form 8
2023-11-06 16:31 ET
Coherus Biosciences published news for 2023 q3
SEC form 10
2023-11-06 00:00 ET
Coherus Biosciences published news for 2023 q3
SEC form 10
2023-08-02 16:11 ET
Coherus Biosciences reported for 2023 q2
SEC form 6
2023-08-02 16:05 ET
Coherus Biosciences published news for 2023 q2
SEC form 10
2023-08-02 00:00 ET
Coherus Biosciences published news for 2023 q2
SEC form 8
2023-08-02 00:00 ET
Coherus Biosciences published news for 2023 q2
SEC form 6
2023-07-20 17:10 ET
Coherus Biosciences published news for 2023 q2
SEC form 6
2023-07-20 17:01 ET
Coherus Biosciences published news for 2023 q2
SEC form 6
2023-06-16 07:06 ET
Coherus Biosciences published news for 2023 q1
SEC form 6
2023-06-15 06:05 ET
Coherus Biosciences published news for 2023 q1
SEC form 6
2023-06-09 17:01 ET
Coherus Biosciences published news for 2023 q1
SEC form 10
2023-05-08 00:00 ET
Coherus Biosciences published news for 2023 q1
SEC form 8
2023-05-08 00:00 ET
Coherus Biosciences published news for 2023 q1
SEC form 6
2023-03-28 18:48 ET
Coherus Biosciences published news for 2022 q4
SEC form 10
2023-03-06 16:16 ET
Coherus Biosciences published news for 2022 q4
SEC form 6
2023-03-06 16:11 ET
Coherus Biosciences published news for 2022 q4
SEC form 10
2023-03-06 00:00 ET
Coherus Biosciences reported for 2022 q4
SEC form 8
2023-03-06 00:00 ET
Coherus Biosciences reported for 2022 q4
SEC form 6
2023-01-12 19:42 ET
Coherus Biosciences published news for 2022 q4
SEC form 10
2022-11-08 16:03 ET
Coherus Biosciences published news for 2022 q3
SEC form 6
2022-11-08 16:01 ET
Coherus Biosciences published news for 2022 q3
SEC form 10
2022-11-08 00:00 ET
Coherus Biosciences reported for 2022 q3
SEC form 8
2022-11-08 00:00 ET
Coherus Biosciences reported for 2022 q3
SEC form 6
2022-10-06 16:06 ET
Coherus Biosciences published news for 2022 q3
SEC form 6
2022-09-15 16:34 ET
Coherus Biosciences published news for 2022 q2
SEC form 6
2022-09-09 17:36 ET
Coherus Biosciences published news for 2022 q2
SEC form 6
2022-09-09 16:46 ET
Coherus Biosciences published news for 2022 q2
SEC form 10
2022-08-04 16:35 ET
Coherus Biosciences published news for 2022 q2
SEC form 6
2022-08-04 16:25 ET
Coherus Biosciences published news for 2022 q2
SEC form 10
2022-08-04 00:00 ET
Coherus Biosciences reported for 2022 q2
SEC form 8
2022-08-04 00:00 ET
Coherus Biosciences reported for 2022 q2
SEC form 6
2022-05-20 17:18 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-20 16:50 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-13 16:44 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-10 16:58 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-06 18:47 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-06 18:43 ET
Coherus Biosciences published news for 2022 q1
SEC form 10
2022-05-05 16:38 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-05-05 16:28 ET
Coherus Biosciences published news for 2022 q1
SEC form 10
2022-05-05 00:00 ET
Coherus Biosciences reported for 2022 q1
SEC form 6
2022-04-04 16:05 ET
Coherus Biosciences published news for 2022 q1
SEC form 6
2022-04-01 16:16 ET
Coherus Biosciences published news for 2022 q1
SEC form 10
2022-02-23 17:29 ET
Coherus Biosciences published news for 2021 q4
SEC form 10
2022-02-23 00:00 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-02-17 16:39 ET
Coherus Biosciences published news for 2021 q4
SEC form 8
2022-02-17 00:00 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-02-07 17:17 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-02-04 20:19 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-01-13 16:39 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2022-01-07 08:36 ET
Coherus Biosciences published news for 2021 q4
SEC form 6
2021-12-03 17:28 ET
Coherus Biosciences published news for 2021 q3
SEC form 10
2021-11-08 16:11 ET
Coherus Biosciences published news for 2021 q3
SEC form 6
2021-11-08 16:06 ET
Coherus Biosciences published news for 2021 q3
SEC form 10
2021-11-08 00:00 ET
Coherus Biosciences published news for 2021 q3
SEC form 8
2021-11-08 00:00 ET
Coherus Biosciences published news for 2021 q3
SEC form 6
2021-10-13 17:01 ET
Coherus Biosciences published news for 2021 q3
SEC form 6
2021-09-29 17:07 ET
Coherus Biosciences published news for 2021 q2
SEC form 6
2021-08-11 16:04 ET
Coherus Biosciences published news for 2021 q2
SEC form 10
2021-08-05 16:19 ET
Coherus Biosciences published news for 2021 q2
SEC form 6
2021-08-05 16:06 ET
Coherus Biosciences published news for 2021 q2
SEC form 10
2021-08-05 00:00 ET
Coherus Biosciences published news for 2021 q2
SEC form 8
2021-08-05 00:00 ET
Coherus Biosciences published news for 2021 q2
SEC form 6
2021-05-26 06:05 ET
Coherus Biosciences published news for 2021 q1
SEC form 10
2021-05-06 16:31 ET
Coherus Biosciences published news for 2021 q1
SEC form 6
2021-05-06 16:24 ET
Coherus Biosciences published news for 2021 q1
SEC form 10
2021-05-06 00:00 ET
Coherus Biosciences published news for 2021 q1
SEC form 8
2021-05-06 00:00 ET
Coherus Biosciences published news for 2021 q1
SEC form 6
2021-04-09 16:05 ET
Coherus Biosciences published news for 2021 q1
SEC form 6
2021-03-16 18:10 ET
Coherus Biosciences published news for 2020 q4
SEC form 10
2021-02-25 16:18 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-02-24 16:05 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-02-12 16:41 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-02-02 08:45 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-01-07 16:32 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-01-07 16:30 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2021-01-07 16:15 ET
Coherus Biosciences published news for 2020 q4
SEC form 6
2020-11-18 16:06 ET
Coherus Biosciences published news for 2020 q3
SEC form 10
2020-11-05 16:17 ET
Coherus Biosciences published news for 2020 q3
SEC form 6
2020-11-05 16:07 ET
Coherus Biosciences published news for 2020 q3